Saudi Honey: A Promising Therapeutic Agent for Treating Wound Infections

Abdulrahman S. Bazaid 1, Abdu Aldarhami 2, Hattan Gattan 3, Bakheet Aljuhani 4

1. Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, Hail, SAU
2. Medical Microbiology, Qunfudah Faculty of Medicine, Umm Al-Qura University, Al-Qunfudah, SAU
3. Medical Laboratory Sciences, King Abdulaziz University, Jeddah, SAU
4. Medical Laboratory Sciences, University of Hail, Hail, SAU

Corresponding author: Abdulrahman S. Bazaid, ar.bazaid@uoh.edu.sa

Abstract
Treatment of wounds, especially chronic ones, is a major challenge in healthcare, with serious clinical and economic burdens. Multiple treatment approaches, including the usage of silver and iodine, have dramatically improved wound healing and reduced the incidence of infection. However, once infected by drug-resistant bacteria, treatment of wounds becomes a serious complication, with limited availability of effective antibiotic drugs, leading to high morbidity and mortality. Therefore, alternative therapeutic agents are required to address this gap in wound management. The introduction of manuka honey as a therapeutic agent against infected wounds was the result of extensive research about its activity against both planktonic and biofilm bacterial growth. Likewise, several types of Saudi honey (e.g., Sidr and Talh) showed promising in vitro and in vivo antimicrobial activity against wound pathogens. This short review summarizes literature that investigated the activity of common types of Saudi honey in relation to wound infections and explores their clinical utility.

Categories: Dermatology, Infectious Disease
Keywords: alternative therapies, saudi honey, manuka honey, antimicrobial resistance, wounds infections

Introduction And Background
Wounds can be defined as breakage or injury of the (superficial or deep) layers of the skin, leading to loss of its integrity and function [1]. Generally, wounds are the outcome of physical, mechanical, or thermal injuries [2]. Clinically, wounds are classified as either acute or chronic, depending on the duration and sequence of healing [1]. Acute wounds heal in up to four weeks and the healing process is defined as follows: inflammation, matrix precipitation, wound contraction, and epithelialization [3]. In contrast, chronic wounds do not follow this healing process and have an extended healing time [1]. Chronic wounds, which are commonly associated with high mortality rates, are triggered by underlying pathologies, such as diabetes, which may cause persistent inflammation [4].

Wound infections
Bacterial colonization of wounds can sometimes be observed without causing an infection [5]. This is because the initiation of bacterial infections within wounds depends on the bacterial load, adaption to the wound conditions, and their respective virulence factors [5]. Additionally, while the diversity of skin microbiota at the site of the wound is altered, whether or not, this contributes to delayed healing is still inconclusive [6]. Wound infections can be caused by Gram-positive (e.g., Staphylococcus aureus and Streptococcus pyogenes) and Gram-negative (e.g., Pseudomonas aeruginosa, Escherichia coli, and Serratia marcescens) bacteria, with varying severity. Infection with S. pyogenes is always considered of high concern due to its serious damage to the skin, known as necrotizing fasciitis [7], while both S. aureus and S. pyogenes have certain virulence factors (e.g., hemolysins) that are associated with impaired wound healing [8,9]. Wound pathogens, including P. aeruginosa and S. aureus, are well-known for their ability to form biofilms through the use of surface proteins (e.g., protein F/SfbI), which adhere to the host cells and enable bacterial aggregation [10]. Biofilms exhibit considerable resistance to antibiotics, which may impair wound healing and deteriorate the clinical outcome [10].

Treating chronic wounds is a major challenge in healthcare globally [1]. There is therefore a need for an urgent and effective therapeutic plan to facilitate wound management and limit potential complications [1]. Wound bed preparation (WBP), a recommended protocol based on clinical practice guidelines, is applied to remove non-viable tissue from a wound, manage exudate, and prevent the establishment of infections [11]. To achieve successful WBP, chronic wounds need to be cleaned with high-pressure water to debride them, as there is no evidence-based recommendation that the use of chemical solutions, such as decylaminodipropyl betaine, leads to better outcomes [11]. Moreover, maintaining a moist wound environment with hydrogels is important to accelerate epithelialization and prevent any further damage by blisters [12]. Systemic antibiotics should only be prescribed in the case of infected wounds, although prophylactic antibiotics are offered to all patients with surgical wounds [13]. Several studies have evaluated the use of topical antimicrobial dressings, such as silver and iodine, for the management of chronic wounds, which revealed a...
significant reduction in S. aureus bacterial load in infected wounds [14,15]. In addition, ionic silver in wound hydrogels has shown promising effects against both planktonic and biofilm bacterial growth [16]. However, resistance to silver was observed in certain wound-infecting bacteria, such as E. coli and Acinetobacter baumannii [17]. Manuka honey, as a natural alternative, was successful in preventing biofilm formation by P. aeruginosa and S. aureus and limited the possibility of developing resistance, making its potential therapeutic use in treating wound infections very promising [18-20].

**Antimicrobial resistance**

Since the discovery of penicillin by Alexander Fleming in 1928, the ongoing use and misuse of antibiotics have led to the emergence of antimicrobial resistance (AMR), where antimicrobial compounds have become less effective against resistant bacteria in the clinical setting [21]. The emergence of multi-drug resistant (MDR) organisms, those resistant to two or more antibiotics classes, has complicated the management of infected wounds [21], and therefore, alternative approaches, including the use of natural products, have been suggested as potential replacement or adjunct treatment with conventional antibiotics [22]. Searching for suitable and effective alternative therapeutic agents to treat infections associated with human wounds, especially those caused by MDR pathogens, has become a world health priority [19].

**Review**

**Honey as a wound remedy**

Honey, as a natural product, has been used by different cultures as a wound remedy over many centuries [19,23], owing to its well-known antimicrobial activity [23]. The antimicrobial activity of honey is attributed to the effect of phenolics, osmotic pressure, and hydrogen peroxide (multiple modes of action), making bacterial resistance less likely to occur [23]. The potency and mode of action of different types of honey differ according to the geographical location, the type of plant used by the bees, and the concentration of the honey [24]. Certain physicochemical components of honey can trigger monocytes to release cytokines, such as interleukin (IL)-1 and IL-6, as well as tumor necrosis factor-alpha (TNF-α), which modulate the immune response to infections (immunomodulation effects) [25].

Recently, a type of honey from New Zealand, Manuka honey, was optimized for use as medical-grade honey for wound dressing [19]. This was the result of observed antimicrobial properties of methylglyoxal, which can promote wound healing and exhibit potent activity against various planktonic and biofilm-forming Gram-positive and Gram-negative pathogenic bacteria, including wound pathogens [19]. Interestingly and importantly, increased in vitro sensitivity was observed in bacterial strains treated with Manuka honey to clinically used antibiotics, compared with untreated bacteria [20].

A recent in vivo study has shown an interesting positive impact upon the healing process of chronic wounds when treated with medical-grade honey (MGH) while the absence of any antibiotic drugs in almost all patients (eight of nine cases) [26]. This is because wound odor, pain, exudation, and signs of wound infections were completely inattentive following the application of the MGH. In addition, the utilize of the MGH has endured an auto-debridement leading to a cleansed wound bed, and well-established granulation tissue and epithelialization. These findings surely supported the potential use of an optimized MGH to treat wound infections and facilitate its healing process.

**Saudi honey**

Saudi honey, e.g., Sidr (Ziziphus spina-christi) honey, showed promising in vitro results against pathogenic drug-resistant bacteria, such as S. aureus, S. mutans, K. pneumonia, and E. coli [27]. The most potent dilution of Sidr honey was determined as 20% (w/v) against S. mutans followed E. coli, S. aureus, and K. pneumoniae based on the optical density of tested bacteria before and after exposure to the honey as follows: 1.809 to 0.359, 1.528 to 0.411, 1.721 to 0.497 and 1.746 to 0.511, respectively [27]. Multiple in vitro studies on the antimicrobial activity of Saudi honey presented various activity profiles and potency levels against tested Gram-positive and Gram-negative pathogenic bacteria [28], according to the source of nectar, the season, and the geographical region [29]. In essence, Sidr and Nigella sativa types of honey (50% w/v) showed an in vitro bacteriostatic effect against wound isolates of imipenem-resistant and sensitive strains of P. aeruginosa, while the same concentration of Manuka honey was shown to have bactericidal activity against the same bacteria [30]. The activity of Sidr honey is variable across different harvest regions, and low concentrations (20% w/v) tend to be more active against Gram-positive than Gram-negative bacteria, while higher concentrations show a broader spectrum of activity [27]. Although no study has report bacterial resistance to honey, Gram-positive isolates of Bacillus cereus and S. aureus exhibited increased in vitro sensitivity to Sidr honey (35% w/v), evidenced by the large zone of inhibition (56 mm and 54 mm, respectively) compared to E.coli and Salmonella enteritidis (27 mm and 23 mm, respectively) [31]. This is in line with previous reports where the inhibition of Gram-positive bacteria (Enterococcus faecalis and S. aureus) at lower the concentration of Manuka honey was observed while its absent/limited effect on Gram-negative bacteria (P. aeruginosa and E. col) [32].

Sidr honey from the Najran region has high in vitro antimicrobial activity (40% w/v) against E. coli (zone of inhibition 30 mm) compared to P. aeruginosa (zone of inhibition 18mm) and A. baumannii (zone of inhibition
19 mm) (Table 1) [33]. By contrast, Sidr honey from the Al-Hasa region showed no in vitro activity (50% w/v) against a wide range of Gram-positive (e.g., *S. aureus, S. epidermidis, S. pyogenes*, and *B. subtilis*) and Gram-negative (e.g., *E. coli, P. aeruginosa, P. mirabilis*, and *S. enterica Typhimurium*) bacteria [34]. Therefore, a different or even a single variety of honey can have variable activity profiles while the observed potency of active products can be relatively similar to commonly used broad-spectrum antibiotics [31].

| Bacteria                        | Honey brand or region | Active concentration | Reference                     |
|---------------------------------|-----------------------|----------------------|-------------------------------|
| *Staphylococcus aureus*         | Alnahal Aljwal        | 21%                  | Hegazi et al., 2017 [27]      |
| *Streptococcus mutans*          |                       |                      |                               |
| *Klebsiella pneumoniae*         | El-Yahia              | 20%                  | Hegazi, 2011 [28]             |
| *Escherichia coli*              |                       |                      |                               |
| *Pseudomonas aeruginosa*        | Valley honey          | 50%                  | Al-Nahari et al., 2015 [30]   |
| *Staphylococcus aureus*         | Middle and Northern regions | 33%                      | Owayss et al., 2020 [31]       |
| *Escherichia coli*              |                       |                      |                               |
| *Pseudomonas aeruginosa*        | Taif                  | 16%                  | Halawani et al., 2011 [35]    |
| *Escherichia coli*              | Asir                  | 20%                  | Ghramh et al., 2019 [36]      |
| *Proteus mirabilis*             |                       |                      |                               |
| *Staphylococcus aureus*         | Al-Baha               | 50%                  | Hussain et al., 2019 [37]     |
| *Staphylococcus epidermidis*    |                       |                      |                               |
| *MSSA*                          |                       |                      |                               |
| *MRSA*                          |                       |                      |                               |
| *Escherichia coli*              | Asir                  | 20%                  | Ghramh et al., 2020 [38]      |

**TABLE 1: Saudi Sidr honey from different regions and brands with various active concentrations against tested pathogenic bacteria.**

MRSA: methicillin-resistant *Staphylococcus aureus*; MSSA: methicillin-sensitive *Staphylococcus aureus*

Talh (*Thymus vulgaris*) honey is another type of Saudi honey, with specific medicinal properties, including promising in vitro activity against pathogenic bacteria [27]. Similar to Sidr honey, Talh honey (33% w/v) is more potent against Gram-positive (*S. aureus and B. cereus*) than Gram-negative (*E. coli and Salmonella enteritidis*) strains (Table 2) [31]. A randomized controlled trial investigated the antimicrobial activity of Saudi Talh honey as a dressing agent against 20 diabetic foot wounds [39]. The use of Talh honey led to a significant reduction (100 fold) in bacterial count (9 x 10^2 CFU) following day 17 of application, compared to bacterial load (9 x 10^4 CFU) recorded after using dressing made of povidone-iodine and saline [39].
Moreover, inflammatory cytokines, mainly IFN-γ, IL-1β, and IL-6, were significantly suppressed (by 12%, 50%, and 55%, respectively), compared with the initial level of response prior to the use of honey [39]. These findings are a clear indication of the in vivo antimicrobial activity of Saudi Talh honey. This activity is often attributed to phenol and hydrogen peroxide, which have been found in high concentrations in these varieties of honey [35].

| Bacteria                        | Honey brand or region | Active concentration | Reference                  |
|---------------------------------|-----------------------|----------------------|----------------------------|
| Staphylococcus aureus           |                       |                      |                            |
| Streptococcus mutans            |                       |                      |                            |
| Klebsiella pneumoniae           | Alnahal Aljwal        | 21%                  | Hegazi et al., 2017 [27]   |
| Escherichia coli                |                       |                      |                            |
| Pseudomonas aeruginosa          |                       |                      |                            |
| Staphylococcus aureus           | Middle and Northern regions | 33%              | Owayss et al., 2020 [31]   |
| Escherichia coli                |                       |                      |                            |
| Salmonella enteritidis          |                       |                      |                            |
| MSSA                            | Al-Baha               | 50%                  | Hussain et al., 2019 [37]  |
| MRSA                            |                       |                      |                            |

**TABLE 2:** Talh Saudi honey from different regions and brands with various active concentrations against tested pathogenic bacteria.

MRSA: methicillin-resistant *Staphylococcus aureus*; MSSA: methicillin-sensitive *Staphylococcus aureus*

Conclusions

Saudi honey has promising activity against a wide range of pathogenic bacteria, with potential use to treat wound infections. Although the activity and level of potency of the tested types of Saudi honey were variable, the most popular varieties of Saudi honey (Sidr and Talh) showed promising broad-spectrum bacteriostatic activity, which seemed to be more potent against Gram-positive bacteria. There remains a need for focused studies to evaluate the potential prophylactic use of Saudi honey against antibiotic-resistant and biofilm-forming bacteria in wounds. Further, systems biology studies to elucidate the impact of Saudi honey on planktonic and biofilm growth of various wound bacteria at the cellular and genomic levels are required. Such data may guide the selection of optimized Saudi honey with higher activity against pathogenic bacteria, with a role as medical-grade honey for treating wound infections.

Additional Information

Disclosures

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Frykberg RG, Banks J: Challenges in the treatment of chronic wounds. Adv Wound Care (New Rochelle). 2015, 4:560-82. 10.1089/wound.2015.0655
2. Church D, Elsayed S, Reid O, Winston B, Lindsay R: Burn wound infections. Clin Microbiol Rev. 2006, 19:403-34. 10.1128/CMR.19.2.403-434.2006
3. Demidova-Rice TN, Hamblin MR, Herman IM: Acute and impaired wound healing: pathophysiology and current methods for drug delivery. part 1: normal and chronic wounds: biology, causes, and approaches to care. Adv Skin Wound Care. 2012, 25:304-14. 10.1097/01.ASW.0000416606.55218.4D
4. Diegelmann RF, Evans MC: Wound healing: an overview of acute, fibrinotic and delayed healing. Front Biosci. 2004, 9:283-9. 10.2741/1184
5. Bowler PG, Duerden BI, Armstrong DG: Wound microbiology and associated approaches to wound management. Clin Microbiol Rev. 2001, 14:244-69. 10.1128/CMR.14.2.244-269.2001
6. Tomic-Canic M, Burgess IL, O’Neill KE, Strbo N, Pastar I: Skin microbiota and its interplay with wound healing. Am J Clin Dermatol. 2020, 21:56-45. 10.1007/s40257-020-00536-w

7. Roje Z, Roje Z, Matić D, Lihrenjak D, Dokuzovic S, Varvodić J: Necrotizing fasciitis: literature review of contemporary strategies for diagnosing and management with three case reports: torso, abdominal wall, upper and lower limbs. World J Emerg Surg. 2011, 6: 10.1186/1749-723X-6-46

8. Strus M, Heczko PB, Golifiska E, et al.: The virulence factors of group A streptococcus strains isolated from invasive and non-invasive infections in Polish and German centres, 2009-2011. Eur J Clin Microbiol Infect Dis. 2017, 36:1645-9. 10.1007/s10096-017-2978-8

9. Ebrahimi A, Ghaseemi M, Ghaseemi B: Some virulence factors of staphylococcus isolated from wound and skin infections in Shahrkord, IR Iran. Jundishapur J Microb. 2014, 7:10.5812/jm.9235

10. Chen X, Lorenzen J, Xu Y, et al.: A novel chronic wound biofilm model sustaining coexistence of Pseudomonas aeruginosa and Staphylococcus aureus suitable for testing of antibiofilm effect of antimicrobial solutions and wound dressings. Wound Repair Regen. 2021, 29:820-9. 10.1111/wrr.12944

11. Sibbald RG, Elliott JA, Persaud-Jaimangal R, et al.: Wound bed preparation 2021. Adv Skin Wound Care. 2021, 34:183-95. 10.1097/01.ASW.00000733724.87630.d6

12. Madaghiele M, Demitri C, Sannino A, Ambrosio L: Polymeric hydrogels for burn wound care: advanced skin wound dressings and regenerative templates. Burns Trauma. 2014, 2:153-61

13. Hernandez R: The use of systemic antibiotics in the treatment of chronic wounds. Dermatol Ther. 2006, 19:526-57. 10.1111/j.1529-8019.2006.00091.x

14. Guthrie HC, Martina KR, Taylor C, et al.: A pre-clinical evaluation of silver, iodine and Manuka honey based dressings in a model of traumatic extremity wounds contaminated with Staphylococcus aureus. Injury. 2014, 45:1171-8.

15. Bigiardi PL, Alasoglu SA, El-Kafrawi HY, Pyon JK, Wu CT, Villa MA.: Povidone iodine in wound healing: a review of current concepts and practices.. Int J Surg. 2017, 44:260-8.

16. Percival SL, McCarty SM: Silver and alginates: role in wound healing and biofilm control. Adv Wound Care (New Rochelle). 2015, 4:407-14. 10.1089/wound.2014.0541

17. McNelly O, Mann R, Hamidian M, Gunawan C: Emerging concern for silver nanoparticle resistance in Acinetobacter baumannii and other bacteria. Front Microbiol. 2021, 12: 10.3389/fmicb.2021.652865

18. Lu J, Cokericin NN, Burke CM, et al.: Honey can inhibit and eliminate biofilms produced by Pseudomonas aeruginosa. Sci Rep. 2019, 9: 10.1038/s41598-019-45476-2

19. Carter DA, Blair SE, Cokercin NN, Bouzo D, Brooks P, Schothauer R, Harry EI: Therapeutic manuka honey: no longer so alternative. Front Microbiol. 2016, 7: 10.3389/fmicb.2016.00569

20. Mokhtar JA, McBain AJ, Ledger RB, Binsuwaidan R, Rimmer V, Humphreys CJ: Exposure to a manuka honey wound gel is associated with changes in bacterial virulence and antimicrobial susceptibility. Front Microbiol. 2020, 11:10.3389/fmicb.2020.02036

21. Ventola CL: The antibiotic resistance crisis: part 1: causes and threats. P T. 2015, 40:277-83.

22. Kim KJ, Liu X, Komabayashi T, Jeong S, Selli S: The antibiotic resistance crisis: part 2: trends and threats. P T. 2015, 40:277-83.

23. Holubová A, Cokerečová L, Cvetková L, Cremers NA, Pokorná A: Honey can inhibit and eliminate biofilms produced by Pseudomonas aeruginosa. Sci Rep. 2019, 9: 10.1038/s41598-019-45476-2

24. Alhussain MB, Kamei YM, Ulhaz Z, Jumna-Fatani AA, Ahmed AS: In vitro evaluation of methicillin-resistant and methicillin-sensitive Staphylococcus aureus susceptibility to Saudi honeys. BMC Complement Altern Med. 2019, 19:10.1186/s12906-019-2605-8

25. Al-Badri AM, Al-Badri AM, Al-Badri AM: The antibacterial activities of honey against Pseudomonas aeruginosa. Saudi J Biol Sci. 2019, 26:1278-84.

26. Ouyay A, Elhaba H, Jalel J, Alburegh H, Organji S, Rawbeh H, Alqarni A: In vitro antimicrobial activities of Saudi honeys originating from Ziziphus spina-christi L. and Acacia gerrardii Benth. trees. Food Sci Nutr. 2020, 8:590-401.

27. Kumar ND, Kalluru RS, Ahmed S, et al.: Comparison of the antibacterial efficacy of manuka honey against E. faecalis and E.coli – an in vitro study. J Clin Diagn Res. 2014, 8:29-31. 10.3774/jcdr.2014.9676.4738

28. Alqurashi AM, Masoud EA, Alamin MA: Antibacterial activity of Saudi honey against Gram negative bacteria. J Microbiol Antimicrob. 2015, 5:1-5.

29. El Din Ghanem NB: A novel chronic wound biofilm model sustaining coexistence of Pseudomonas aeruginosa and Staphylococcus aureus suitable for testing of antibiofilm effect of antimicrobial solutions and wound dressings. Wound Repair Regen. 2021, 29:820-9. 10.1111/wrr.12944

30. Almasaudi S: Therapeutic manuka honey: no longer so alternative. Front Microbiol. 2016, 7: 10.3389/fmicb.2016.00569
39. Hegazi AG, Al Guthami FM, Basiouny MH, Al Gethami FM: Topical Saudi Arabia Talh honey (Acacia nilotica) on surgical wound healing activity. Highlights Biosci. 2020, X:10.36462/H.BioSci.20220